The management of neovascular age-related macular degeneration (nAMD) continues to advance with therapies designed to improve visual outcomes while reducing treatment burden. Understanding the mechanisms of newer intravitreal agents is increasingly important in contemporary retinal practice. Test your knowledge with this quick question on the management of neovascular AMD! (Scroll down to answer the question) ##Reference## Heier JS, Khanani AM, Quezada Ruiz C; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet.
2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. PMID: 35085502. ##Disclaimer## The content provided on Docplexus is intended for…
